Last updated on November 2017

Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine


Brief description of study

Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine

Detailed Study Description

The study is being conducted to evaluate two doses of TEV-48125 in adult patients with episodic migraine

Clinical Study Identifier: TX82083

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Patient Recruitment

Cedar Crosse Research Center
Chicago, IL USA
  Connect »